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Evolution of the domain encoding the V1/V2 variable region of the simian immunodeficiency virus sm
(SIVsm) envelope (env) gene was analyzed in relation to route of virus challenge, virus load, and neutralizing
antibody (NAb) titers during primary infection of rhesus macaques with the pathogenic SIVsmE660 isolate. In
this model system animals are initially infected with multiple viruses as evidenced by the presence of multiple
V1/V2 genotypic variants that could be resolved by using a heteroduplex tracking assay (HTA). Overlapping
subsets of the multiple variants were established in each animal. There was no selection for the establishment
of specific variants in comparing intravenous- and intrarectal-challenged macaques at week 2 postinfection,
suggesting that no genotypic selection occurred at the mucosal surface. There was an initial period of
significant stability of the V1/V2 variants. Macaques challenged intravenously displayed subsequent V1/V2
diversification significantly earlier than macaques challenged intrarectally and well past the initial resolution
of viremia. The time when SIVsmE660-specific NAbs reached a threshold titer of 100 was significantly
correlated with the timing of V1/V2 diversification, even though antibodies to the Env protein could be detected
much earlier. The time when NAbs reached a titer of 400 was significantly correlated with virus load late in
infection. These results show that the route of infection affects the timing of V1/V2 diversification and that this
diversification is correlated with the maturation of a specific NAb response. However, prior immunization
capable of priming an anamnestic Env antibody response did not accelerate V1/V2 diversification. This result
suggests that diversification of the SIV env V1/V2 region is the result of a type-specific antibody response.
Both the human immunodeficiency virus type 1 (HIV-1) and
the simian immune virus (SIV) envelope (Env) proteins con-
tain variable regions (12, 34). The V1/V2 variable regions are
a multifunctional domain on Env that undergoes a conforma-
tional change upon CD4 binding (46, 56), modulates exposure
of the coreceptor binding site on Env (55), can contribute to
cell tropism and cytopathicity (20, 42), and contains epitopes
for antiviral antibodies (22, 31, 49). The V1/V2 region, along
with the other variable regions, represents regions of the viral
genome that express remarkable capacity to evolve in response
to changing selective pressures within the host.
Systemic and mucosal infection represent two major routes
of HIV-1 entry into human hosts. Several studies have exam-
ined viral evolution in relation to route of infection (29, 48, 50,
51). These results suggested that mucosal barriers act as selec-
tive filters for HIV-1 genotypes.
The development of host neutralizing antibodies (NAbs) as
part of the humoral response against HIV-1 and SIV most
often occurs after the resolution of peak plasma viremia (43,
45). The variable regions on the HIV-1 and SIV Env proteins
can serve as linear and conformational epitopes for NAbs (1, 9,
21, 22). Changes in the variable regions enable the virus to
escape neutralization by antibodies developed early after in-
fection, allowing virus populations to persist (5, 52). Virus
variants that develop after infection are commonly character-
ized by sequence changes, length changes, and changes in the
carbohydrate composition of the V1/V2, namely alterations in
N-linked and O-linked glycosylation sites (1, 7, 53, 55). In
addition, the route of exposure to antigen in vaccine presen-
tation, and potentially in infection, can affect the nature of the
immune response (26, 57).
The analysis of env heterogeneity has yielded and will con-
tinue to yield important information about the biology of the
viral Env protein. We have focused on the heterogeneity of the
V1/V2 variable region to track changes in env gene popula-
tions, although other regions of env are amenable to similar
analysis. We have examined the effect of site of entry on virus
uptake and the rate of evolution as measured by V1/V2 diver-
sification. We found no evidence for sequence selection during
entry at a mucosal surface. However, our results show that
V1/V2 diversification occurs significantly later in macaques
challenged mucosally (intrarectally [i.r.]) than with macaques
challenged systemically (intravenously [i.v.]), although there
was no significant difference in the total Env antibody response
by these two routes. The timing of V1/V2 diversification was
correlated with the antiviral NAb titer but was not correlated
with peak virus load (VL) or set point viremia levels. The
initial changes in V1/V2 amino acid sequences that were ob-
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served in macaques challenged i.v. and i.r. were similar and
were characterized primarily by changes in a region of poten-
tial O-linked glycosylation sites in V1. Prior vaccination primed
an anamnestic response, as measured by a neutralization assay
specific for SIVsmH-4 and enzyme-linked immunosorbent as-
say (ELISA) specific for gp120, but did not affect the timing of
V1/V2 diversification, suggesting strong type specificity in the
V1/V2 immune response. Taken together, these results suggest
that the route of virus entry affects the timing of V1/V2 diver-
sification and that the heterogeneity of the SIV env V1/V2
region is correlated with a type-specific antibody response.
MATERIALS AND METHODS
SIV challenge and vaccination. After passage of SIVsm through a rhesus
macaque, the uncloned challenge virus, SIVsmE660, was isolated as previously
described (15, 19). Macaques (in groups of six) were challenged either i.v. with
1 ml of a 1:6,000 dilution of the virus stock (50% macaque infectious dose) or
i.r. with 1 ml of undiluted virus stock of SIVsmE660. However, two of the
nonvaccinated macaques challenged i.v. in this study had undetectable plasma
VL throughout the postinfection (p.i.) period and were not demonstrated to be
infected by any other test and therefore were not included in this analysis.
Another group of 8 macaques was vaccinated with SIVsmH4-derived matrix/
capsid (MA/CA), gp140 and gp160 genes expressed by using the Venezuelan
equine encephalitis virus (VEE) vector system (10). Each VEE vector dose was
107 infectious units given subcutaneously in the right forelimb. Data on the
efficacy of the vaccination protocol will be presented separately. Four of these
macaques were challenged i.v. and four macaques were challenged i.r. with
SIVsmE660 as described above. Another two macaques from a previous study
(10) were also examined in a separate analysis to determine the effect of rapid
disease progression. These macaques (N2P and W1A) were sacrificed at week
11 p.i. in that previous study due to severe wasting (10). All animal care was
performed in accordance with institutional guidelines.
Virus load determination and NAb titers. Virus load was determined by the
bDNA assay (Chiron, Emeryville, Calif.). NAb titers against SIVsmE660 and
SIVsmH-4 (18) were determined by CEMx174 and H9 cell-killing assays, respec-
tively, as previously described (35). The values shown are the reciprocal of the
dilution of serum needed to protect 50% of the cells from virus-induced killing.
SIVsmE660 is a virus stock from an isolate generated from a macaque infected
with the SIVsm isolate (18). SIVsmH-4 is an infectious molecular clone from the
SIVsm isolate (18) that was used as a source of viral genes for immunization and
as the source of the heteroduplex tracking assay (HTA) probe and was also used
to generate a virus stock for NAb assays.
ELISA. Purified SIVsmH-4 gp120 protein was diluted with carbonate buffer
(7.5 mM Na2CO3–17.4 mM NaHCO3, pH 9.6) and then added to wells (200
ng/well) and incubated overnight. The plates were washed with phosphate-buff-
ered saline (PBS) and were incubated for 1 h with blocking buffer (3% bovine
serum albumin plus 1% normal rabbit sera diluted in PBS). The wells were
washed with PBS. Diluted macaque plasma was added to the wells, and the plate
was incubated for 1 h at room temperature. The wells were washed, and then
rabbit anti-monkey immunoglobulin G-conjugated horseradish peroxidase anti-
bodies (Sigma, St. Louis, Mo.) were added and incubated for 1 h. The wells were
washed, and color development was performed by using OPD FAST Tablets
(Sigma) per the manufacturer’s protocol. The plates were read at an optical
density of 450 nm (OD450). Titers are reported as the reciprocal of the highest
dilution that yields an OD reading of 0.200.
RNA isolation and RT-PCR. Viral RNA was isolated from 140 l of macaque
plasma by using the QIAamp viral RNA isolation kit (Qiagen, Valencia, Calif.),
resulting in purified RNA in a 50-l volume. Briefly, the V1/V2 region of the env
gene was reverse transcribed by using a modified Titan One Tube RT-PCR
System (Roche Applied Science, Indianapolis, Ind.). Primers specific for the
V1/V2 region used for reverse transcription-PCR (RT-PCR) were the following:
5-GTGGAACCTCTTTGAAACATCCATTAAGCC-3 (smH-4/V1) and 5-GT
GCACAGTATCTAAATCTAATAGCATCCC-3 (smH-4/V2). RT-PCR was
performed as follows. The 20-l reaction mixture consisted of 5 l of purified
viral RNA, 1 Titan RT-PCR buffer, 5 mM dithiothreitol, 1 mM each de-
oxynucleoside triphosphate, 10 pmol of V2 primer, and 12 U of avian myelo-
blastosis virus reverse transcriptase. RT was carried out at 42°C for 30 min. A
30-l aliquot of PCR mix (1 Titan RT-PCR buffer, 5 mM dithiothreitol, 10
pmol of V1 primer, and 0.5 l of Titan enzyme mix) was then added to the RT
reaction mixture. PCR was carried out in a Robocycler 40 (Stratagene, La Jolla,
Calif.) with the following program: 1 cycle of 95°C for 3 min, 54°C for 1 min, and
72°C for 1 min, and 39 cycles of 95°C 1 min, 54°C for 1 min, and 72°C for 1 to
4 min, followed by a final cycle at 72°C for 7 min.
V1/V2 probe construction. The V1/V2 sequence was amplified from the
SIVsmH-4 molecular clone (19) by using primers smH-4/V1 and smH-4/V2 to
produce a 430-bp fragment that was inserted into the pT7Blue plasmid by
blunt-end ligation (Novagen, Madison, Wis.) to generate the plasmid
pSIVsmH-4V1/V2. An aliquot of 5 g of plasmid DNA was linearized with
EcoRI at 37°C for 1 h. The probe in the EcoRI reaction was labeled by filling in
the 3 underhang after adding 10 mM dithiothreitol, 50 Ci of [35S]dATP (1,250
Ci/mmol; NEN Life Science Products), and 10 U of Klenow fragment of DNA
polymerase I for 15 min at room temperature. The labeled probe was then
released from the vector by digestion with XbaI at 37°C for 1 h. Excess radio-
active nucleotide was removed by using a MicroSpin G-50 column (Amersham
Pharmacia Biotech, Arlington Heights, Ill.), and the volume was adjusted to 100
l.
V1/V2 HTA. V1/V2 heteroduplex annealing mixtures consisted of 1 anneal-
ing buffer (0.1 M NaCl, 10 mM Tris-HCl [pH 7.5], 2 mM EDTA), 5 to 10 l of
unpurified RT-PCR product, and 1 l of labeled V1/V2 smH-4 probe in a total
volume of 10 l. The annealing mixture was incubated at 99°C for 2 min to
denature the DNA and then was allowed to anneal at room temperature for 5
min. The heteroduplexes were separated in 6% polyacrylamide (37:5:1 acryl-
amide-bisacrylamide) gels in 1 Tris-borate-EDTA buffer (0.09 M Tris-borate,
0.002 M EDTA). Heteroduplexes were visualized by autoradiography of dried
HTA gels. Dried gels were also exposed to phosphorimaging screens to quanti-
tate the relative abundance of the bands in each sample by using ImageQuant
software (Molecular Dynamics, Sunnyvale, Calif.). Two independent RT-PCRs
were performed from each viral RNA preparation followed by HTA analysis as
described above, which validated adequate sampling in that the same complex
patterns were reproducibly observed.
Measure of V1/V2 diversification. The relative abundance of each variant was
calculated as a percent of the total population of genotypic variants at each time
point. In an effort to quantitate subsequent diversification, we used the group of
genotypic variants present in each animal at week 2 p.i. as the baseline and
quantitated the appearance of new genotypic variants in subsequent samples
using the following formula: Divx  100  Ex, where E represents the variants
that were established by week 2 p.i., Ex represents the percent fraction of those
variants remaining at week x, and Divx represents the percentage of new variants
at week x. Td50 is defined as the time when half of the relative abundance of
variants identified by HTA were attributed to variants not found at week 2 p.i.
The Mann-Whitney rank sum test was used to determine the statistical signifi-
cance between values from the i.v.- and the i.r.-challenged groups. Pearson
product moment correlation statistics were used to determine the significance of
correlations between two variables.
Sequence analysis. RT-PCR products of interest were purified by using the
QIAquick PCR purification kit (Qiagen) and were cloned by using the pT7Blue
Perfectly Blunt cloning kit. Inserts in individual clones were amplified by using
primers smH-4/V1 and smH-4/V2 by PCR as described above. The products
were screened by V1/V2-HTA with the SIVsmH-4V1/V2 probe. Plasmids were
sequenced by ABI dye terminator sequencing (Perkin-Elmer Corp., Foster City,
Calif.) and were analyzed and aligned with MacVector 7.0 (Genetics Computer
Group, Madison, Wis.).
Nucleotide sequence accession numbers. The sequences described in this study
were deposited in GenBank with the accession numbers AY492288 to
AY492335.
RESULTS
Characterization of the V1/V2 region of the SIVsmE660
isolate. We constructed an HTA probe for the SIVsm V1/V2
region of env from the SIVsmH-4 molecular clone (18). We
used this probe to assess the complexity of the SIVsmE660
isolate, which was used as the challenge virus. This analysis
showed a heteroduplex pattern consisting of three major
V1/V2 variants in the SIVsmE660 stock (Fig. 1A, bands A, B,
and C). Band A clones consisted of two distinct V1/V2 popu-
lations represented by sequences A1 and A2 (Fig. 1B), which
differed by two nucleotide substitutions in V2 but comigrated
in the HTA gel. Several changes distinguished the SIVsmH-4
probe from all of the SIVsmE660 variants, but the changes
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that distinguished the SIVsmE660 variants from each other
largely consisted of insertions of threonines and other sub-
stitutions in the threonine-rich region of V1. The
SIVsmE660 stock was used to challenge macaques through the
i.v. or i.r. route, and V1/V2 env diversification was assessed
during primary infection. Undiluted virus stock was used in the
i.r. challenge versus a 1:6,000 dilution of the virus for the i.v.
challenge to compensate for the lower efficiency of infection by
a mucosal route compared to that by an i.v. route.
Transmission and initial viremia. We used the smH-4
V1/V2 probe to analyze V1/V2 diversity to determine which
V1/V2 variants were established in each host at week 2 p.i.
Only a subset of the variants present in the complex
SIVsmE660 stock became established in most animals, while only
macaques AV96 (Fig. 2A), AV06, and AV89 (Fig. 2C) acquired
all three of the major SIVsmE660 variants. A visual analysis of the
V1/V2 HTA patterns at week 2 p.i. did not reveal a correspon-
dence between route of challenge and which V1/V2 variants be-
came established in each host (Fig. 2A and C). The presence of
SIVsmE660 V1/V2 viral variants A, B, and C (as shown in Fig. 1)
was scored for each animal. The percentage of animals showing
the respective SIVsmE660 variants at week 2 p.i. was calculated
for each challenge group (Fig. 2B and D). These results showed
no significant difference between i.v.- and i.r.-challenged animals
with respect to the subset of SIVsmE660 V1/V2 variants estab-
lished in each animal. These results suggest that the route of
challenge, either i.v. or i.r., did not differ with respect to tissue-
specific selective determinants that would bias the establishment
of a subset of the SIVsmE660 challenge virus when administered
at these two sites. All macaques showed typical peak viremia at
2 to 3 weeks p.i., and the levels of peak VL were not significantly
different between macaques challenged i.v. or i.r. (Table 1).
Resolution of viremia. The initial decline in viremia was
reached by week 6 p.i. in most animals. There was a remark-
able level of stability in the composition of the V1/V2 env
population through week 8 p.i. HTA analysis showed that 8 out
of 10 nonvaccinated macaques maintained stable V1/V2 pop-
ulations through week 8 p.i., indicating that initial viremia was
resolved without detectable changes in V1/V2 sequences re-
gardless of infection route (Fig. 3). This suggests that, during
the initial resolution of viremia, there is no apparent compe-
tition between these V1/V2 variants and no apparent selective
pressure by the host directed at V1/V2. This observation is
consistent with a cytotoxic T-lymphocyte (CTL) response re-
solving the initial viremia between week 2 to 6 p.i (2, 24, 38),
although we have not examined other regions of env for early
diversification. One example of where a CTL response may
have occurred at or near V1/V2 is shown in the HTA analysis
of macaque PDW, where a change in relative abundance of
two V1/V2 variants appears during the transition between
weeks 3 and 4 p.i. followed by stability (Fig. 3A). Macaque
AV96 showed a slow outgrowth of a V1/V2 variant between
week 3 and week 12 p.i. (Fig. 3B, asterisk). Notably, no new
V1/V2 variants were detected in these two macaques beyond
those established variants during week 2 to 8 p.i., similar to the
cases of the other eight macaques analyzed.
We examined the initial antibody response by using an
ELISA assay to measure the level of anti-gp120 antibodies in
the plasma of each animal starting at week 7 p.i. Anti-gp120
antibodies were detected in all animals at week 7 p.i., and the
levels of antibodies were not significantly different between
i.v.- and i.r.-challenged macaques (Table 1). Neutralization
assays were performed to quantitate the subset of effective
antibodies present in the plasma of each macaque at week
7 p.i. Detectable NAbs were present in all animals using the
SIVsmH-4 variant in neutralization assays, with a trend toward
higher NAb titer in the i.r.-challenged animals (P  0.067)
(Table 1). However, neutralization assays against the challenge
FIG. 1. Analysis of the V1/V2 region from SIVsmE660. (A) HTA
analysis of SIVsmE660 V1/V2 region. Bands A, B, and C represent the
three major V1/V2 variants seen in the SIVsmE660 inoculum. Single
asterisks represent single-stranded probe, and double asterisks repre-
sent double-stranded probe. The PCR product for the SIVsmH-4
control was generated from cloned DNA. In this system, the homodu-
plex with PCR product is designed to migrate slightly more slowly than
the probe reannealed to itself. (B) Amino acid sequence alignments
of V1/V2 regions of SIVsmH-4 and the major V1/V2 variants in
SIVsmE660. Dots represent identical amino acids. Dashes represent
deleted amino acids. Short lines above the sequence highlight N-linked
glycosylation sites. A1 and A2 represent different sequences from
clones of the PCR product that comigrated with band A in the HTA
gel. The frequency of sequences from clones is indicated at the right of
each sequence.
FIG. 2. Established V1/V2 variants at week 2 p.i. (A) HTA analysis
of V1/V2 variants detected in plasma at week 2 p.i. from nonvaccinated
macaques. (B) Histogram representing the percentage of nonvacci-
nated macaques scored for the presence of each SIVsmE660 variant
shown in Fig. 1. (C) HTA analysis of V1/V2 variants detected in
plasma at week 2 p.i. from vaccinated macaques. (D) Histogram rep-
resenting the percentage of vaccinated macaques scored for the pres-
ence of each SIVsmE660 variant shown in Fig. 1. If a viral variant did
not correspond with variants A, B, or C in the original SIVsmE660
inoculum, it was scored as other. In panels B and D white bars repre-
sent i.v.-challenged macaques and black bars represent i.r.-challenged
macaques.
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virus SIVsmE660 showed detectable, albeit low, NAb levels in
all of the i.v.-challenged macaques and only one i.r.-challenged
macaque (P  0.048) (Table 1). SIVsmH-4 is easy to neutralize
in vitro, whereas the SIVsmE660 mixture is difficult to neutral-
ize, similar to typical primary isolates (D. Montefiori, unpub-
lished data). These results suggest a qualitative, although not
quantitative, difference in the early antibody response depend-
ing on an i.v. versus a mucosal challenge.
Initial diversification of V1/V2. In general, there was a dra-
matic loss of the initially established V1/V2 variants at a point
some time after week 8 p.i., with the appearance of new vari-
ants indicating a primary phase of V1/V2 diversification. We
measured the time at which one-half of the V1/V2 population
represented new variants, defined as Td50, as a way to com-
pare the rate of env diversification between animals and be-
tween challenge groups. Note that this calculation omits
changes in the relative abundance of the transmitted variants
(as in AV96 and PDW) to draw attention to the appearance of
new variants. These results showed that there was a significant
difference between Td50 values in the i.v. group (mean at week
10 p.i.) and the i.r. group (mean at week 18 p.i.) (P  0.01).
The difference in timing of env diversification between the i.v.-
and i.r.-challenged groups was apparent even though there was
no significant difference in the level or day of the initial peak
viremia or in virus set point levels (Table 1). Since VL has been
shown to be a predictor of the rate of progression to AIDS (17,
32, 33), we wanted to determine if VL is also associated with
the timing of V1/V2 diversity in the macaque cohort. Scatter
plots of Td50 values and corresponding peak VL values and set
point VL levels for the i.v.- and i.r.-challenged animals showed
no significant correlation (data not shown). Together, these
data suggest that the timing of peak VL, level of VL peak, and
set point viremia do not play a role in the observed differences
in the timing of V1/V2 diversity between macaques challenged
i.v. and i.r.
Correlation between Td50 and NAb100 titers to the challenge
virus. Previous work has shown that the resolution of the initial
viremia is correlated with the appearance of CTL activity,
which precedes the appearance of NAbs (13, 38). We hypoth-
esized that the delayed diversification of env after the resolu-
tion of the initial viremia would reflect the evolution of a NAb
response. The time at which NAb to the challenge virus,
SIVsmE660, could be detected at a 1:100 dilution (NAb100)
was used as a measure of NAb response, because this titer is
significantly above the level of detection (a 1:20 dilution) in the
assay. Although NAb100 values showed the same trend as Td50
values, the NAb100 values did not significantly differ between
the i.v.- and i.r.-challenged macaques (P  0.171). However, a
scatter plot representing the relationship between Td50 and
corresponding NAb100 values showed a significant correlation
for the nonvaccinated macaques (Fig. 4; r  0.83, P  0.003).
Thus, env V1/V2 diversification is correlated with the evolution
of a host NAb response subsequent to the initial resolution of
viremia. Given the surface location of V1/V2 on the Env pro-
tein we presume that the selective pressure driving diversifica-
tion is the host humoral response.
Maturation of a NAb response. After initial viremia was
resolved, V1/V2 diversity continued to increase beyond the
Td50 point for a majority of the macaques, as indicated by the
HTA patterns and as quantitated by average percent diversity
for i.v.- and i.r.-challenged macaques (Fig. 5A). Significant
differences in average percent diversity between i.v.- and i.r.-
challenged macaques were observed at weeks 12, 16, and 20 p.i.
(Fig. 5A). In contrast, there was no difference in the kinetics of
the evolution of an antibody response to Env as measured by
ELISA, with the i.r.-challenged animals having equivalent or
higher titers at most time points (Fig. 5B). Similarly, we mea-
sured no consistent difference in the average NAb response to
SIVsmE660 in comparing these two groups (Fig. 5B). Thus,
V1/V2 diversification may be a more sensitive measure of the
presence of selective pressure on this region of the Env protein
than the measure of bulk NAb to the challenge virus.
The VL patterns between weeks 24 and 41 p.i. are dynamic
in most of the animals (Fig. 3), suggesting that the virus and
host have not reached a steady state. Therefore, to begin to
assess the long-term effect of a NAb response, we examined
the VL at the last time point available (week 41 p.i.) with the
time of evolution of a stronger host NAb response to the
challenge virus, SIVsmE660; i.e., a titer of 400. A significant
correlation between NAb400 and VL at week 41 p.i. is evident
(Fig. 6; r  0.811, P  0.027). Macaques JJW, KXA, and AU86
were not included in this analysis, because NAb titers to
SIVsmE660 did not reach 400 during the p.i. time period.
These results suggest that the rate of establishment of a NAb
response, as measured by the time required to reach a NAb
TABLE 1. VL and NAb dynamics of SIV-naive macaquesc
Macaque Group VL peak(wk p.i.; P  0.610)
VL peak
(copies/ml; P  0.257)
VL set pointa
(copies/ml; P  0.915)
gp120b ELISA
(wk 7 p.i.; P  0.610)
NAb titerb smH-4
(wk 7 p.i.; P  0.067)
NAb titerb smE660
(wk 7 p.i.; P  0.048d)
JJW i.v. 2 1.7  107 1.5  105 500 1,239 35
KXA i.v. 3 8.7  106 8.6  104 2,500 3,037 79
PDW i.v. 2 4.0  107 2.5  105 1,000 2,084 20
TDB i.v. 2 1.5  107 1.9  106 4,000 7,188 26
AU86 i.r. 2 8.7  105 4.5  105 2,000 12,728 20
AV87 i.r. 2 3.6  107 9.4  106 200 6,343 20
AU91 i.r. 2 1.2  106 4.4  104 4,000 9,676 20
AV95 i.r. 2 8.2  106 3.3  106 4,000 8,544 20
AV96 i.r. 2 2.6  106 1.9  103 1,000 2,956 20
PKC i.r. 2 2.2  107 3.2  105 8,000 8,701 61
a Determined by calculating the geometric mean of bDNA values between wk 24 and 41.
b Values represent the inverse of serum dilution.
c P values were determined by Mann-Whitney rank sum test.
d Determined by Fisher exact test for the presence or absence of NAb against SIV smE660 comparing i.v.- and i.r.-challenged groups.
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titer of 400, is in part predictive of VL outcome in nonvacci-
nated macaques.
V1/V2 sequence evolution. V1/V2 variants from pre- and
post-Td50 time points were cloned and sequenced from ma-
caques JJW (i.v.), TDB (i.v.), AV95 (i.r.), and AU91 (i.r.) (Fig.
7). Most of the variability between clones from the pre-Td50
point was confined to the center of the V1 region. In contrast,
the V2 region showed no length variation and little sequence
variation in the clones analyzed. Comparing pre- and post-
Td50 time points, V1/V2 sequence analysis from these four
macaques showed numerous amino acid changes in the V1
region in i.v.- and i.r.-challenged animals characterized by
serine and threonine changes, suggesting additions and dele-
tions of O-linked glycosylation sites. These results support
previous studies showing changes in glycosylation sites in V1
during the time of infection (40, 41). However, there was no
discernible difference in the pattern of sequence variability
between i.v. and i.r. challenge groups, suggesting that major
FIG. 3. V1/V2 evolution in i.v. (A) and i.r. (B) challenge groups. Left panels show the HTA autoradiograms of longitudinal plasma samples
using the SIVsmV1/V2 probe. Numbers above lanes indicate the week p.i. Graphs show VL (circle), NAb titers to SIVsmE660 (triangle), and the
percent diversity (square) at the indicated week p.i. The designated identifier of the animal is shown above each set of panels.
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sequence changes occur in V1 regardless of challenge route
but only differ in the timing of when these changes occur.
These results suggest that the initial selective pressure on V1/
V2, presumably by host antibodies, is largely directed at V1. In
this analysis, we do not know if the sequence variants evolved
de novo in each host or represented a minor variant present in
the transmitting stock that grew out in the face of selective
pressure on the major variants.
Lack of V1/V2 diversification in rapid progressors. In a
related study (10), two macaques challenged with SIVsmE660
through the i.v. route had a rapid disease course after failing to
resolve the initial viremia. The virus population in these ani-
mals showed changes only in the relative abundance of estab-
lished V1/V2 variants, and no new V1/V2 variants were de-
tected (Fig. 8). The NAb titers measured against SIVsmH-4
were below detection at week 8 p.i., and no reactivity to Env
was observed in ELISA assays (data not shown). These results
suggest that very high VL associated with rapid disease pro-
gression blunts the initial humoral response and precludes the
establishment of host selective pressures that drive V1/V2 di-
versification.
Effect of vaccination on V1/V2 diversification. As part of a
vaccine efficacy study, eight macaques were immunized with an
alphavirus vector expressing SIVsmH-4 genes. The SIVsmH-4
molecular clone was generated from the same virus isolate that
was used to generate the SIVsmE660 challenge stock. Thus,
the cloned genes used in the vaccination are related but not
identical to the more complex SIVsmE660 isolate mixture,
which was generated from an infected animal and expanded in
culture. We used the smH-4 V1/V2 env probe to analyze which
V1/V2 variants were established at week 2 p.i. in macaques
that were vaccinated with SIVsmH-4-derived genes and chal-
lenged with SIVsmE660 via the i.v. or IR route. In most of the
vaccinated macaques a subset of the variants present in the
complex SIVsmE660 stock became established in each host
(Fig. 2C). Scoring for the presence of the SIVsmE660 variants
A, B, and C showed similar proportions of each variant in both
i.v.- and i.r.-challenged animals after vaccination (Fig. 2D).
Prior vaccination primed for an anamnestic response as indi-
cated by the presence of elevated levels of NAbs to SIVsmH-4
at week 2 (Table 2) and in the elevated gp120 ELISA titer
(data not shown) in the vaccinated animals. However, HTA
analysis of V1/V2 diversification in the vaccinated macaques
showed that the V1/V2 HTA pattern was stable between weeks
2 to 8 p.i., and resolution of viremia was not associated with
changes in V1/V2 (data not shown). There was no significant
FIG. 4. Correlation between Td50 and SIVsmE660 NAb titers.
Td50 values and NAb100 values are plotted for all of the nonvaccinated
animals. The solid line represents the correlation for nonvaccinated
animals (r  0.83, P  0.003).
FIG. 5. Antibody response to SIV infection. Open symbols repre-
sent nonvaccinated i.v.-challenged macaques and closed symbols rep-
resent nonvaccinated i.r.-challenged macaques. (A) Plots represent av-
erage percent diversity during infection. (B) Plots represent averaged
ELISA antibody titers against gp120 (circles) and SIVsmE660-specific
NAb titers (squares) in plasma. Error bars represent standard errors.
FIG. 6. Correlation between NAb400 and endpoint VL. The week
p.i. when NAb titers to SIVsmE660 reached 400 was estimated from
the graphs shown in Fig. 3. The VL at week 41 p.i. was determined by
bDNA assay. Two of the i.v.-infected animals did not reach a titer of
400 and are not included in this analysis.
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difference in the time to V1/V2 diversification between non-
vaccinated and vaccinated animals. Differences between Td50
values in i.v.- and i.r.-challenged macaques were not as signif-
icant as those seen with nonvaccinated macaques, but similar
trends were observed whereby V1/V2 diversification occurred
later in i.r.-challenged macaques than in i.v.-challenged ma-
caques (data not shown). Thus, V1/V2 diversification dynamics
occurred similarly in both nonvaccinated and vaccinated ma-
caques in spite of the fact that the vaccination primed for an
anamnestic response to the SIVsmH-4 Env protein.
DISCUSSION
The results of this investigation suggest that the route of
virus entry into a host affects the timing of the initial evolution
of the SIV env V1/V2 region. Detectable changes in the V1/V2
FIG. 7. Analysis of V1/V2 sequences before and after corresponding Td50. Italic lettering indicates pre-Td50 sequences. Other sequences are
post-Td50 sequences. Dots represent identical amino acids. Dashes represent deleted amino acids. Solid lines above sequences represent N-linked
glycosylation sites. The frequency of the specific sequence from clones generated from the PCR product are indicated at the right of each sequence.
Inferred amino acid sequence was derived from the nucleotide sequence.
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region occurred significantly earlier in animals infected system-
ically (i.v.) rather than across a mucosal surface (i.r.). In con-
trast, although different V1/V2 variants became established
within each animal among the i.v.- and IR-challenged ma-
caques (Fig. 2), there was no specific selection of variants that
could establish an infection via the i.v. or i.r. routes. Thus,
specific mutations, at least as linked to V1/V2 genotypic vari-
ants, did not seem to play a discriminating role in establishing
the initial infection. Previous studies have shown that the route
of infection can be a determinant of the complexity of the
transmitted variants (16, 48). The results of these studies sug-
gested that mucosal transmission leads to a relatively simple
composition of genotypic variants in plasma, perhaps as the
result of selection at the mucosal site, whereas a complex virus
population becomes established in most of the i.v.-challenged
macaques (16, 48). In these studies, the same amount of virus
was administered by i.v. and at the mucosal site. In our study,
macaques infected by the mucosal route were inoculated with
undiluted virus stock to compensate for lower efficiency of
mucosal challenge. After compensating for differences in trans-
mission efficiency by these different routes, we did not observe
a difference in the complexity or composition of transmitted
V1/V2 variants between i.v.- and i.r.-challenged macaques
(Fig. 2).
The acute phase of infection (weeks 2 to 8 p.i.) was not
accompanied by changes in V1/V2, as was evident in the HTA
analysis (Fig. 3 and 8), suggesting that early VL dynamics are
not correlated with the initial diversification of V1/V2. In ad-
dition, CTL escape by mutation has been measured and shown
to occur as early as week 4 p.i., suggesting that the virus is able
to escape some cellular immune pressures during the acute
phase of infection (38). Thus, the stability of V1/V2 popula-
tions during the resolution of viremia suggests that V1/V2 is
not an early target of a CTL response. We do note that one
animal (PDW; Fig. 3) had a rapid transition between V1/V2
variants at the time of viremia resolution, suggesting a closely
linked CTL epitope. These results on the early stability of
V1/V2 variants are in contrast to those of Learn et al., who
suggested that an initially diverse HIV-1 env population (in
humans) undergoes a contraction in complexity, at least within
the C2-V5 regions (25).
Induction of antibodies against the HIV-1 and SIV Env
protein are an integral (and the relevant) component of the
host humoral immune response to viral infection (4, 6, 30, 36).
Specifically, NAbs have been suggested to influence V1/V2
evolution (5, 39). We suggest that the diversification of V1/V2
reported here was driven by antibody selection, although some
of the data are inconclusive. When using the data from all 10
nonvaccinated macaques, we found a correlation between the
evolution of a moderate NAb response and V1/V2 diversifica-
tion (Fig. 4), with both occurring significantly later for IR-
challenged animals. Consistent with this finding, we observed a
trend toward a qualitative difference in the antibody response
between i.v.- and i.r.-challenged animals at week 7 p.i. (Table
1). However, there was no difference between i.v.- and i.r.-
challenged animals in the total antibody response (ELISA),
nor was there a consistent difference in the NAb response over
the time course (Fig. 5B). Thus, while there is an overall
correlation between NAbs and V1/V2 diversification, it is less
apparent that differences in the timing of the appearance of
NAbs accounts for the differences in the diversification of
V1/V2 between i.v.- and i.r.-challenged animals. Studies such
as these are limited by the small numbers of animals available.
In support of our interpretation is the observation that in a
separate vaccinated group of macaques there was a similar
trend of early diversification of V1/V2 in i.v.-challenged ani-
mals and late diversification in i.r.-challenged animals. We
believe this indicates that there is a qualitative difference in the
virus-host interaction that is dependent on the route of infec-
tion. The correlation between the timing of V1/V2 diversity
and a NAb response (Fig. 4) supports the hypothesis that
V1/V2 evolution is a sensitive measure of the appearance of a
NAb response during SIV infection or at least an antibody
response capable of providing selective pressure sufficient to
favor the outgrowth of genetic variants.
Although our hypothesis is that NAbs influence V1/V2 di-
FIG. 8. HTA analysis of the V1/V2 region of macaques that did not
resolve initial viremia. (A) HTA autoradiograms of plasma samples
using the SIVsmV1/V2 probe. Numbers above lanes indicate week p.i.
(B) Graph of VL measurements as determined by bDNA assay. Both
macaques were sacrificed at week 11 p.i.




Titer at wk p.i.:
1 2 7
Non vaccinated
i.v. 20 20 2,740 	 1,319a
i.r. 20 20 7,455 	 1,341
Vaccinated
i.v. 49 	 11 9,657 	 9,418 13,025 	 2,839
i.r. 50 	 7 970 	 807 16,240 	 1,515
a Error values represent standard errors.
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versity, NAb titers apparently trailed V1/V2 diversity in 7 out
of 10 nonvaccinated macaques (Fig. 4). A possible explanation
for this observation is that NAbs are present prior to V1/V2
diversification but are not detected against the SIVsmE660
isolate used in the neutralization assay. NAbs were detected
against SIVsmH-4 at week 7 p.i. in all macaques in this study
(Table 1), suggesting that NAbs specific for SIVsmH-4-specific
epitopes are present prior to V1/V2 diversification. Previous
work has shown that the SIVsmH-4 variant is a sensitive
indicator of NAbs, and in vitro neutralization assays using
SIVsmH-4 seem to detect epitope specificities that are ei-
ther absent or not adequately exposed on SIVsmE660 (10).
In addition, since only a subset of the SIVsmE660 V1/V2
variants became established within each host (Fig. 2), the in
vitro neutralization assay against the complete SIVsm E660
mixture may underestimate the neutralizing potential of
antibodies within each animal. The delayed appearance of
SIVsmE660-specific NAbs suggests a lengthier maturation of
an SIVsmE660-specific NAb response. Others have reported a
general phenomenon of lentiviruses characterized by a com-
plex and lengthy maturation of specific NAb development (8,
37, 43, 44, 47) and that evolution of virus-specific antibody
responses are independent of the pathogenicity of the virus
strain used for infections (8). However, rapid disease progres-
sion can be associated with a blunting of the immune response
and a reduction of genotypic diversity in both SIVsm-infected
macaques (Fig. 8 and reference 27) and HIV-1-infected hu-
mans (11, 14, 54).
It was somewhat surprising that vaccination with the
SIVsmH-4 env gene was able to prime an anamnestic response
for Env antibodies and for SIVsmH-4 NAbs (Table 2) but did
not alter the timing of V1/V2 diversification. This implies that
the V1/V2 region of the H-4 Env protein was not an effective
immunogen for the E660 variants. The likely explanation is
that the sequence differences between H-4 V1/V2 and the
E660 variants (Fig. 1) represent changes that confer a type-
specific antibody response. The production of an anamnestic
response for SIVsmH-4 neutralizing antibodies indicates that
the E660 complex is displaying these epitopes. If these anti-
bodies apply selective pressure on variants in the E660 mixture
it may be possible to identify the target region (epitopes) of the
SIVsmH-4 NAbs as having early sequence changes in the vac-
cinated animals. Testing this hypothesis will require sequenc-
ing larger regions of the env genes generated from vaccinated
and nonvaccinated animals.
What could be the difference in the virus-host interaction
initiated by different routes of infection that would affect the
timing of V1/V2 diversification? Virus production after a mu-
cosal infection might occur at sites that are less accessible to
selective pressures of antibodies, although the total plasma VL
is not different as a function of route. Alternatively, V1/V2
antigen presentation or the capacity/response of B cells and/or
T-helper cells may differ by compartment in the face of an
infection. Finally, gp120 conformations available to the im-
mune system may differ as a function of compartment, reflect-
ing different proportions of particle-associated gp120, cell sur-
face-associated gp120, or shed soluble gp120. The difference in
NAbs to SIVsmH-4 and SIVsmE660 at week 7 p.i. (Table 1)
suggests a qualitative difference in the antibody response as a
function of route.
The long-term partial control of viremia by the host is likely
to be the result of interplay between a number of factors. We
found a correlation between the time at which a strong NAb
response evolved (titer of 400) and VL at week 41 p.i. (Fig. 6).
However, this analysis did not include three animals that had
moderate VL but never reached this NAb titer, pointing to the
complexity of this system. Schmitz et al. have observed a rela-
tionship between NAb and set point (47). These observations
support the idea that a strong NAb response is either a con-
tributor to or a marker of more effective control of the VL.
However, contradicting this conclusion is the observation that
when animals were primed by vaccination for an anamnestic
response, there was no correlation between the timing of the
appearance of a potent NAb titer and VL at week 41 p.i. (data
not shown).
There are numerous glycosylation sites in the V1/V2 region,
and changes in glycosylation sites could mask antibody recog-
nition of neutralizing epitopes on Env (6). For three of the
animals examined by sequence, substitutions in V1 either
added or removed threonines within V1, possibly changing
O-linked glycosylations (Fig. 7). In the fourth animal examined
more complex substitutions occurred in V1 (AU91; Fig. 7B).
Only in one animal did we detect changes related to N-linked
glycosylations within this region (TDB; Fig. 7A). The homo-
geneous runs of threonines on SIVsm differ from the AXU
codon motif encoding Thr, Ser, and Asn within V1, V2, and V4
of HIV-1, suggesting a difference in the nature of sequence
diversity between SIVsm and HIV-1 (3, 23). It is not clear to
what extent these changes in potential O-linked glycosylation
sites work in cis or at distal sites as proposed for the HIV-1
glycan shield (53).
Because the SIVsmE660 variant is a heterogeneous viral
population, the model presented here approximates exposure
of a host to genetically diverse variants at primary infection.
Multiple variants have been reported in women recently in-
fected with HIV-1 (28), and we have observed that 50% of
subjects in primary HIV-1 infection have multiple V1/V2 pop-
ulations (K. Ritola and R. Swanstrom, unpublished data). We
have also observed the coexistence of multiple V1/V2 variants
late in HIV-1 infection (23), in the chronic stages of HIV-1
infection (K. Ritola and R. Swanstrom, unpublished) and after
the initial diversification of V1/V2 in macaques (Fig. 3). These
coexisting variants may represent the presence of individually
evolved type-specific variants independently populating niches
determined by an incomplete host immune response. These
results show how env diversification is affected by route of virus
entry and host immune pressures and suggest that the V1/V2
response may be highly type specific.
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